Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Clinical trial NCT06838832 · RECRUITING

Trial details

NCT number: NCT06838832
Sponsor: Chinese PLA General Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-hodgkin Lymphoma,B Cell

Start date: 2025-07-27
Primary completion: 2027-03-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.